Dacryocystitis: Difference between revisions

(Text replacement - "==Treatment==" to "==Management==")
(Text replacement - "0 mg" to "0mg")
Line 21: Line 21:
==Management==
==Management==
*Oral [[clindamycin]] for 7-10 days
*Oral [[clindamycin]] for 7-10 days
*If ill appearing: IV [[cephalosporin]] ([[cefuroxime]] 50 mg/kg IV Q8h or [[cefazolin]] 33 mg/kg IV Q6H) or [[clindamycin]] (10 mg/kg IV Q8H)
*If ill appearing: IV [[cephalosporin]] ([[cefuroxime]] 50mg/kg IV Q8h or [[cefazolin]] 33 mg/kg IV Q6H) or [[clindamycin]] (10mg/kg IV Q8H)
**If [[MRSA]] suspected: [[Vancomycin]] 10-13 mg/kg IV Q6-8 h
**If [[MRSA]] suspected: [[Vancomycin]] 10-13 mg/kg IV Q6-8 h
*Chronic dacryocystitis: topical antibiotic ([[fluoroquinolone]] or [[erythromycin]])
*Chronic dacryocystitis: topical antibiotic ([[fluoroquinolone]] or [[erythromycin]])

Revision as of 18:53, 18 July 2016

Background

  • Acute or chronic inflammation and bacterial infection of the lacrimal sac
    • Most common pathogens: Strep. pneumoniae, staph. aureus, staph. epidermidis, h. influenzae
  • Most common in children
  • Often after viral URI
  • Complications: Periorbital Cellulitis, Orbital Cellulitis

Clinical Features

  • Mucopurulent material expressed from nasolacrimal sac
  • Erythema and edema between medial canthus and nasal bridge

Diagnosis

  • Physical exam
  • May culture purulent material

Differential Diagnosis

Periorbital swelling

Proptosis

No proptosis

Lid Complications

Other

Neonatal eye problems

Management

References

  • Tintinalli 7th ed, p. 764